Biocytogen’s Asia-Pacific business development team is pleased to host online 1-on-1 meetings at BIO Asia-Taiwan, taking place from July 25-26, 2023! Chat with our team to learn more about our animal models, preclinical services and antibody assets in discovery.
BioMice: Innovative Models to Empower Health Sciences
BioMice is a sub-brand of Biocytogen dedicated to providing preclinical models and pharmacology research services. To date, 1600+ gene edited animal and cell models have been generated for drug discovery and efficacy evaluation. This includes 560+ target humanized mouse models, 120+ humanized cell lines, 40+ immunodeficient mouse models engineered for relieved GvHD and better engraftment of human T and/or NK cells, and 770+ target knock-out mice.
Using these off-the-shelf models, we also provide preclinical pharmacology evaluation services, including in vivo/ex vivo efficacy, PK/PD, pilot toxicity/safety studies and in vitro cell based assays to evaluate novel antibody-based drugs prior to clinical development.
Using these off-the-shelf models, we also provide preclinical pharmacology evaluation services, including in vivo/ex vivo efficacy, PK/PD, pilot toxicity/safety studies and in vitro cell based assays to evaluate novel antibody-based drugs prior to clinical development.
We are proud to have provided our innovative animal models to more than 20 countries/regions, and have contracted more than 2000 preclinical pharmacology and efficacy evaluation services for over 400 clients worldwide.
Download Our BioMice Product List and Service Brochures
Antibodies Available for Licensing
As part of Biocytogen’s Project Integrum, our antibody R&D team has identified 686 antibody hits, 10+ fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies and 50+ GPCR targeted programs, using our RenMice for fully human antibody discovery. These assets are available for licensing and/or co-development. Learn More:
Browse Our Off-the-Shelf Fully Human Antibodies
Whether you’re interested in learning more about BioMice models and pharmacology services, or antibody discovery platforms and assets, we look forward to exploring collaboration opportunities with you!
